Finance
Novo Nordisk to halve US list price of Wegovy from 2027
Published by Global Banking & Finance Review®
Posted on February 24, 2026
1 min readLast updated: February 24, 2026
Tags:healthcare
Quick Summary
Reuters reports, citing WSJ, that Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027. The move targets affordability and intensifies competition with Eli Lilly.
Feb 24 (Reuters) - Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday.
The price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same drugs under federal Medicare health plans for older adults.
The market for so-called GLP-1 drugs has been getting increasingly competitive, while the broader shift to consumer-driven cash-pay channels is making price points more sensitive.
Both Ozempic and Wegovy will list for $675 a month from next year, half the current price for Wegovy and a 35% cut for diabetes treatment Ozempic.
The price cuts also will apply to Wegovy and Rybelsus pills.
This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving U.S. healthcare system, the company said.
(Reporting by Padmanabhan Ananthan and Sriparna Roy in Bengaluru; Editing by Leroy Leo)
Key Takeaways
- •Novo Nordisk plans to reduce U.S. list prices for Ozempic and Wegovy by up to 50%.
- •Cuts are slated to begin in 2027, according to WSJ reporting cited by Reuters.
- •The move aims to improve affordability and access for U.S. patients.
- •Price reductions could pressure rivals such as Eli Lilly and influence GLP-1 pricing.
- •The announcement has implications for NVO, LLY and broader healthcare markets.
Frequently Asked Questions about Novo Nordisk to halve US list price of Wegovy from 2027
1What is the main topic?
Novo Nordisk plans to cut U.S. list prices for its GLP-1 drugs Ozempic and Wegovy by up to 50%, as first reported by the Wall Street Journal and cited by Reuters.
2When will the price cuts begin?
The reductions are slated to start in 2027, according to the WSJ report referenced by Reuters.
3Why is Novo Nordisk lowering prices?
The move is aimed at boosting affordability and access for patients and may respond to rising competition and policy pressure in the U.S.
